Mousavi S, Nouri S, Sadeghipour A, Atashi A
Ann Hematol. 2025; .
PMID: 39994019
DOI: 10.1007/s00277-025-06237-w.
Dubois N, Crompot E, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B
Front Oncol. 2020; 10:1422.
PMID: 32974152
PMC: 7466743.
DOI: 10.3389/fonc.2020.01422.
Gupta R, Yan X, Barrientos J, Kolitz J, Allen S, Rai K
J Immunol. 2018; 201(5):1570-1585.
PMID: 30068596
PMC: 6103916.
DOI: 10.4049/jimmunol.1800591.
Al-Kahiry W, Sharshira H, Ghanem A, El-Gammal M, Mikhael I
Indian J Hematol Blood Transfus. 2017; 33(3):321-326.
PMID: 28824232
PMC: 5544636.
DOI: 10.1007/s12288-016-0745-0.
Purroy N, Wu C
Cold Spring Harb Perspect Med. 2017; 7(4).
PMID: 28096240
PMC: 5378011.
DOI: 10.1101/cshperspect.a026740.
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.
Herishanu Y, Katz B, Lipsky A, Wiestner A
Hematol Oncol Clin North Am. 2013; 27(2):173-206.
PMID: 23561469
PMC: 3660068.
DOI: 10.1016/j.hoc.2013.01.002.
Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.
Gehrke I, Gandhirajan R, Poll-Wolbeck S, Hallek M, Kreuzer K
Mol Med. 2011; 17(7-8):619-27.
PMID: 21519633
PMC: 3146618.
DOI: 10.2119/molmed.2010.00210.
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.
Damle R, Calissano C, Chiorazzi N
Best Pract Res Clin Haematol. 2010; 23(1):33-45.
PMID: 20620969
PMC: 2921990.
DOI: 10.1016/j.beha.2010.02.001.
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer L, Egle A, Hartmann T, Greil R
Nat Rev Clin Oncol. 2009; 6(7):405-18.
PMID: 19488076
DOI: 10.1038/nrclinonc.2009.72.
Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification.
Gurrieri C, McGuire P, Zan H, Yan X, Cerutti A, Albesiano E
J Exp Med. 2002; 196(5):629-39.
PMID: 12208878
PMC: 2194006.
DOI: 10.1084/jem.20011693.
Growth and survival of B-chronic lymphocytic leukaemia cells.
Soderberg O
Med Oncol. 1998; 15(2):73-8.
PMID: 9789213
DOI: 10.1007/BF02989583.
Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region.
Flenghi L, Bigerna B, Fizzotti M, Venturi S, Pasqualucci L, Pileri S
Am J Pathol. 1996; 148(5):1543-55.
PMID: 8623923
PMC: 1861546.
Benign and malignant (B cell) focal lymphoid aggregates in bone marrow trephines shown by means of an immunogold-silver technique.
Sangster G, Crocker J, Nar P, Leyland M
J Clin Pathol. 1986; 39(4):453-7.
PMID: 3084596
PMC: 499845.
DOI: 10.1136/jcp.39.4.453.
Receptors for the third component of complement: their association with maturation stage in non-Hodgkin lymphomas (NHL) and their possible implication with the development of follicular structures.
Greil R, Gattringer C, Schulz T, Knapp W, Radaskiewicz T, Dierich M
Clin Exp Immunol. 1986; 64(2):423-31.
PMID: 2943542
PMC: 1542352.
Isolation of multicellular complexes of follicular dendritic cells and lymphocytes: immunophenotypical characterization, electron microscopy and culture studies.
Ennas M, Chilosi M, Scarpa A, Lantini M, CADEDDU G, FIORE-DONATI L
Cell Tissue Res. 1989; 257(1):9-15.
PMID: 2752415
DOI: 10.1007/BF00221628.
Dendritic reticulum cell-related immunostaining for laminin in follicular and diffuse B-cell lymphomas.
Gloghini A, Carbone A
Virchows Arch A Pathol Anat Histopathol. 1990; 416(3):197-204.
PMID: 1689086
DOI: 10.1007/BF01678978.
